Abstract
AbstractThe recommended antiviral drugs available for the treatment and prevention of influenza are neuraminidase inhibitors (NAIs). The aim of this study was to evaluate age-related clinical manifestations of adverse events (AEs) related to NAIs. FAERS and WebMD data were downloaded. The available NAIs selected for the analysis were oseltamivir, peramivir, zanamivir, and laninamivir. Disproportionality was analyzed using the proportional reporting ratio (PRR), the reporting odds ratio (ROR), and the information component (IC) methods. In total, 16729 AEs from 4598 patients and 575 AEs from 440 patients in the FAERS and WebMD, respectively, were included in the analysis. In the FAERS, AEs were more common among those who were younger (<19 years) for zanamivir, while for those who were older (>65 years) for peramivir. A disproportionality analysis showed that signals for vomiting and hallucinations were detected in younger patients given oseltamivir, while an abnormal hepatic function, cardiac failure, shock, and cardio-respiratory arrest were detected in older patients given peramivir. Psychiatric disorders were most common in younger and older patients, while gastrointestinal disorders were most common in adult given oseltamivir in the WebMD. Adverse symptoms related to NAIs varied and depended on the drugs used and the age of the patient.
Funder
the National Research Foundation of Korea grant funded by the Korea government (MSIT)
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. World Health Organization Influenza (Seasonal) Fact Sheet N. 211, https://www.who.int/news-room/detail/11-03-2019-who-launches-new-global-influenza-strategy [(accessed on 13 July 2018)]
2. Available online, http://www.who.int/mediacentre/factsheets/2003/fs211/en/). (2019).
3. Lindmeier, C. WHO launches new global influenza strategy, https://www.who.int/news-room/detail/11-03-2019-who-launches-new-global-influenza-strategy. (2019).
4. Gupta, Y. K., Meenu, M. & Mohan, P. The Tamiflu fiasco and lessons learnt. Indian. J. Pharmacol. 47, 11–16 (2015).
5. Heneghan, C. J. et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348, g2547 (2014).
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献